Extracellular Superoxide Dismutase Is Associated With Left Ventricular Geometry and Heart Failure in Patients With Cardiovascular Disease.
Extracellular Superoxide Dismutase Is Associated With Left Ventricular Geometry and Heart Failure in Patients With Cardiovascular Disease.
复制标题
细胞外超氧化物歧化酶与心血管疾病患者的左心室几何形状和心力衰竭相关
DOI：
10.1161/jaha.120.016862
复制
发表时间：
2020-08-04
影响因子：
5.4
通讯作者：
Xia M
中科院分区：
文献类型：
--
作者：
Li X;Lin Y;Wang S;Zhou S;Ju J;Wang X;Chen Y;Xia M
细胞外超氧化物歧化酶（Ec-SOD）是活性氧的主要清除剂。然而，在心血管疾病患者中，其与左心室（LV）几何形态异常和心力衰竭（HF）的关系仍不清楚。进行了一项横断面研究，以评估 1047 名心血管疾病患者的血清 Ec-SOD 活性与左心室几何形状以及心力衰竭的关系。所有参与者均接受标准超声心动图检查和血清 Ec-SOD 活性测量。总体而言，我们发现在调整潜在混杂因素后，正常几何形状受试者 (147.96±15.94 U/mL)、左心室几何形状异常但无心力衰竭的受试者 (140.19±20.12 U/mL) 以及左心室几何结构异常和明显心力衰竭 (129.32±17.92 U/mL) 受试者的血清 Ec-SOD 活性呈显着下降趋势（趋势 P <0.001）。按不同左心室几何形态分层后，向心肥厚组和偏心肥厚组的下降趋势仍然显着。多项 Logistic 回归分析显示，血清 Ec-SOD 活性每增加 10 U/mL，无 HF 的同心重塑的几率就会降低 16.5%（优势比 [OR]，0.835；95% CI，0.736–0.948），有 HF 的同心肥大的几率会降低 40.4%（OR，0.596；95% CI，0.736-0.948）。 95% CI, 0.486–0.730)，不伴心力衰竭的偏心肥大的几率降低 16.1%（OR，0.839；95% CI，0.729–0.965），伴心力衰竭的偏心肥大的几率降低 34.0%（OR，0.660；95% CI， 0.565–0.772)。血清 Ec-SOD 活性与伴有或不伴有明显心力衰竭的异常左心室几何形态独立相关。我们的结果表明，Ec-SOD 可能是心血管疾病患者左心室结构重塑与后续心力衰竭发展之间的潜在联系。网址：https://www.clinicaltrials.gov；唯一标识符 NCT03351907。
Extracellular superoxide dismutase (Ec‐SOD) is a major scavenger of reactive oxygen species. However, its relationships with abnormal left ventricular (LV) geometry patterns and heart failure (HF) are still unknown in patients with cardiovascular disease. A cross‐sectional study was carried out to evaluate the association of serum Ec‐SOD activity with LV geometry, as well as HF in 1047 patients with cardiovascular disease. All participants underwent standard echocardiography examination and measurement of serum Ec‐SOD activity. Overall, we found a significantly decreased trend of serum Ec‐SOD activity from subjects with normal geometry (147.96±15.94 U/mL), subjects with abnormal LV geometry without HF (140.19±20.12 U/mL), and subjects with abnormal LV geometry and overt HF (129.32±17.92 U/mL) after adjustment for potential confounders (P for trend <0.001). The downward trends remained significant in the concentric hypertrophy and eccentric hypertrophy groups after stratification by different LV geometry patterns. Multinomial logistic regression analysis showed that each 10 U/mL increase in serum Ec‐SOD activity was associated with a 16.5% decrease in the odds of concentric remodeling without HF (odds ratio [OR], 0.835; 95% CI, 0.736–0.948), a 40.4% decrease in the odds of concentric hypertrophy with HF (OR, 0.596; 95% CI, 0.486–0.730), a 16.1% decrease in the odds of eccentric hypertrophy without HF (OR, 0.839; 95% CI, 0.729–0.965) and a 34.0% decrease in the odds of eccentric hypertrophy with HF (OR, 0.660; 95% CI, 0.565–0.772). Serum Ec‐SOD activity was independently associated with abnormal LV geometry patterns with and without overt HF. Our results indicate that Ec‐SOD might be a potential link between LV structure remodeling and the development of subsequent HF in patients with cardiovascular disease. URL: https://www.clinicaltrials.gov; Unique identifier NCT03351907.